PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
Safi U KhanSiva H YedlapatiAhmad N LoneQiukui HaoGordon GuyattNicolas DelvauxGeertruida E Trudy BekkeringPer Olav VandvikIrbaz Bin RiazSheyu LiBert AertgeertsNicolas RodondiPublished in: BMJ (Clinical research ed.) (2022)
Ezetimibe or PCSK9 inhibitors may reduce non-fatal MI and stroke in adults at very high or high cardiovascular risk who are receiving maximally tolerated statin therapy or are statin-intolerant, but not in those with moderate and low cardiovascular risk.